Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Alumis Inc. Common StockNASDAQ: ALMS
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 58.0% from a year ago
Cash & equivalents stood at $63.71M at the end of Q2 FY2026, down 58.0% from a year earlier and down 0.3% from the prior quarter. Over 3 fiscal years it compounded at +51.8% a year.
Context
- Cash & equivalents amounted to 11.4% of total assets at the end of Q2 FY2026, down 13.5 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -58.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 89.67M USD
- Year-over-year change
- -47.1%
- 3-year CAGR
- +51.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 89.67M | -47.1% |
| FY2024 | 2024-12-31 | 169.53M | +268.6% |
| FY2023 | 2023-12-31 | 46M | +79.6% |
| FY2022 | 2022-12-31 | 25.61M | — |
Cash & Equivalents vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -58.0% is the 7th highest of 9, against a peer median of -18.3%.
- Cash & equivalents amounts to 11.4% of total assets for ALMS, versus a peer median of 30.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $248.47M USD | +151.9% | +49.5% | 75.4% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €129.59M EUR | — | — | 78.2% |
| Mar 2026 | $65M USD | +29.1% | -21.4% | 97.8% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $63.71M USD | -58.0% | +51.8% | 11.4% |
| Mar 2026 | $28.66M USD | -5.6% | -23.9% | 14.4% | |
| Mar 2026 | $24.99M USD | -80.0% | +6.4% | 25.0% | |
| Mar 2026 | $24.41M USD | -46.6% | +18.4% | 4.8% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $20.96M USD | -31.1% | -36.1% | 19.8% |
| Mar 2026 | €15.01M EUR | -68.3% | -0.5% | 30.7% | |
| Dec 2025 | $4.01M USD | +7.7% | -39.5% | 34.9% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -18.3% | -11.0% | 30.7% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.